NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Clinical trial NCT07077551 · RECRUITING
Trial details
- NCT number
- NCT07077551
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-22
- Primary completion
- 2028-12-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.